Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Vecabrutinib |
Synonyms | |
Therapy Description |
Vecabrutinib (SNS-062) inhibits BTK, including BTK mutations associated with inhibitor resistance, which potentially results in decreased tumor growth (Mol Cancer Ther December 1 2015 (14) (12 Supplement 2) C186). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Vecabrutinib | SNS-062|BSK-4841|BIIB-062|BIIB062 | BTK inhibitor 37 | Vecabrutinib (SNS-062) inhibits BTK, including BTK mutations associated with inhibitor resistance, which potentially results in decreased tumor growth (Mol Cancer Ther December 1 2015 (14) (12 Supplement 2) C186). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BTK G409R | mantle cell lymphoma | resistant | Vecabrutinib | Preclinical - Cell culture | Actionable | In a preclinical study, a mantle cell lymphoma cell line developed resistance to Vecabrutinib (SNS-062) after prolonged exposure in culture, and was subsequently found to have acquired BTK G409R (PMID: 36661329). | 36661329 |
BTK C481S | chronic lymphocytic leukemia | sensitive | Vecabrutinib | Preclinical - Cell culture | Actionable | In a preclinical study, Vecabrutinib (SNS-062) inhibited viability of a chronic lymphocytic leukemia cell line harboring BTK C481S (PMID: 34662393). | 34662393 |
BTK C481S | diffuse large B-cell lymphoma | sensitive | Vecabrutinib | Preclinical - Cell culture | Actionable | In a preclinical study, Vecabrutinib (SNS-062) treatment inhibited viability of a diffuse large B-cell lymphoma cell line harboring BTK C481S in culture (PMID: 35196427). | 35196427 |
BTK E41K BTK C481S | Advanced Solid Tumor | predicted - sensitive | Vecabrutinib | Preclinical - Biochemical | Actionable | In a preclinical study, Vecabrutinib (SNS-062) inhibited Plcg2 activity in cells expressing BTK E41K and BTK C481S in an in vitro assay (PMID: 34662393). | 34662393 |
BTK A428D | diffuse large B-cell lymphoma | resistant | Vecabrutinib | Preclinical - Cell culture | Actionable | In a preclinical study, a diffuse large B-cell lymphoma cell line expressing BTK A428D demonstrated resistance to Vecabrutinib (SNS-062) in culture (PMID: 35196427). | 35196427 |
BTK E41K | Advanced Solid Tumor | predicted - sensitive | Vecabrutinib | Preclinical - Biochemical | Actionable | In a preclinical study, Vecabrutinib (SNS-062) inhibited Plcg2 activity in cells expressing BTK E41K in an in vitro assay (PMID: 34662393). | 34662393 |
BTK V416L | diffuse large B-cell lymphoma | resistant | Vecabrutinib | Preclinical - Cell culture | Actionable | In a preclinical study, a diffuse large B-cell lymphoma cell line expressing BTK V416L demonstrated resistance to Vecabrutinib (SNS-062) in culture (PMID: 35196427). | 35196427 |
BTK L528W | diffuse large B-cell lymphoma | resistant | Vecabrutinib | Preclinical - Cell culture | Actionable | In a preclinical study, a diffuse large B-cell lymphoma cell line expressing BTK L528W demonstrated resistance to Vecabrutinib (SNS-062) in culture (PMID: 35196427). | 35196427 |
BTK T474I | diffuse large B-cell lymphoma | resistant | Vecabrutinib | Preclinical - Cell culture | Actionable | In a preclinical study, a diffuse large B-cell lymphoma cell line expressing BTK T474I demonstrated resistance to Vecabrutinib (SNS-062) in culture (PMID: 35196427). | 35196427 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03037645 | Phase Ib/II | Vecabrutinib | Safety, PK, PD, and Antitumor Activity of SNS-062 in B Lymphoid Cancers | Terminated | USA | 0 |